These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 37999900)

  • 1. Outcomes of patients with esophageal squamous cell carcinoma who achieved a pathological complete response in the primary lesion by neoadjuvant treatment: a Japanese nationwide cohort study.
    Okamura A; Watanabe M; Okui J; Matsuda S; Takemura R; Kawakubo H; Kakeji Y; Kono K; Kitagawa Y; Takeuchi H
    Esophagus; 2024 Jan; 21(1):2-10. PubMed ID: 37999900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic factors for esophageal squamous cell carcinoma without pathological lymph node metastasis after neoadjuvant therapy and surgery.
    Hamai Y; Emi M; Ibuki Y; Murakami Y; Nishibuchi I; Kurokawa T; Yoshikawa T; Hirohata R; Ohsawa M; Kitasaki N; Okada M
    World J Surg; 2024 Feb; 48(2):416-426. PubMed ID: 38310312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of neoadjuvant chemotherapy versus upfront surgery with or without chemotherapy for patients with clinical stage III esophageal squamous cell carcinoma.
    Matsuda S; Tsubosa Y; Sato H; Takebayashi K; Kawamorita K; Mori K; Niihara M; Tsushima T; Yokota T; Onozawa Y; Yasui H; Takeuchi H; Kitagawa Y
    Dis Esophagus; 2017 Feb; 30(2):1-8. PubMed ID: 26919154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncologic Outcomes According to Remnant Lymph Node Metastases in Pathologic T0 (ypT0) Esophageal Squamous Cell Carcinoma Following Prospective Neoadjuvant Therapy and Surgery.
    Cho HJ; Kim YH; Kim HR; Kim DK; Park SI; Kim JH; Kim SB
    Ann Surg Oncol; 2015; 22(6):1851-7. PubMed ID: 25344308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors for recurrence of esophageal squamous cell carcinoma after pathological complete response to neoadjuvant therapy followed by esophagectomy.
    Hirohata R; Hamai Y; Emi M; Ibuki Y; Kurokawa T; Ohsawa M; Kitasaki N; Okada M
    World J Surg; 2024 Jul; 48(7):1700-1709. PubMed ID: 38757868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SUV
    Nagaki Y; Motoyama S; Sato Y; Wakita A; Fujita H; Sasaki Y; Imai K; Minamiya Y
    World J Surg Oncol; 2021 Apr; 19(1):105. PubMed ID: 33836789
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognosis of Patients With Pathologic T0 N+ Esophageal Squamous Cell Carcinoma After Chemoradiotherapy and Surgical Resection: Results From a Nationwide Study.
    Chao YK; Chen HS; Wang BY; Hsu PK; Liu CC; Wu SC
    Ann Thorac Surg; 2016 May; 101(5):1897-902. PubMed ID: 26912307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncologic Outcome of Patients With Pathologic T0 Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemoradiotherapy.
    Chen SB; Wang X; Chen YP
    Cancer Control; 2024; 31():10732748241284905. PubMed ID: 39259832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of pathological tumor response and residual nodal metastasis in patients with esophageal squamous cell carcinoma after neoadjuvant chemotherapy followed by surgery.
    Oguma J; Ozawa S; Koyanagi K; Kazuno A; Yamamoto M; Ninomiya Y; Yatabe K
    Esophagus; 2019 Oct; 16(4):395-401. PubMed ID: 31190104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk prediction of esophageal squamous cell carcinoma recurrence in patients who underwent esophagectomy after receiving neoadjuvant treatment: a nationwide retrospective study in Japan.
    Okamura A; Watanabe M; Okui J; Matsuda S; Takemura R; Kawakubo H; Takeuchi H; Muto M; Kakeji Y; Kitagawa Y; Doki Y
    Esophagus; 2023 Jul; 20(3):465-473. PubMed ID: 37029845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Supraclavicular and/or celiac lymph node metastases from thoracic esophageal squamous cell carcinoma did not compromise survival following neoadjuvant chemoradiotherapy and surgery.
    Cho WK; Oh D; Ahn YC; Shim YM; Zo JI; Sun JM; Ahn MJ; Park K
    Oncotarget; 2017 Jan; 8(2):3542-3552. PubMed ID: 27682879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinicopathological Significance of Pathologic Complete Lymph Node Regression After Neoadjuvant Chemoradiotherapy in Esophageal Squamous Cell Carcinoma.
    Hsu PK; Yeh YC; Chien LI; Huang CS; Hsu HS
    Ann Surg Oncol; 2021 Apr; 28(4):2048-2058. PubMed ID: 33216266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic Impact of Postoperative Lymph Node Metastases After Neoadjuvant Chemoradiotherapy for Locally Advanced Squamous Cell Carcinoma of Esophagus: From the Results of NEOCRTEC5010, a Randomized Multicenter Study.
    Leng X; He W; Yang H; Chen Y; Zhu C; Fang W; Yu Z; Mao W; Xiang J; Chen Z; Yang H; Wang J; Pang Q; Zheng X; Liu H; Yang H; Li T; Zhang X; Li Q; Wang G; Mao T; Guo X; Lin T; Liu M; Fu J; Han Y
    Ann Surg; 2021 Dec; 274(6):e1022-e1029. PubMed ID: 31855875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Residual lymph node status is an independent prognostic factor in esophageal squamous cell Carcinoma with pathologic T0 after preoperative radiotherapy.
    Wang Q; Yu S; Xiao Z; Liu X; Zhang W; Zhang X; He J; Sun K; Xu T; Feng Q; Zhou Z; Wang L; Yin W
    Radiat Oncol; 2015 Jul; 10():142. PubMed ID: 26159510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for the treatment of esophageal squamous cell carcinoma: a propensity score-matched study from the National Cancer Center in China.
    Zhang G; Zhang C; Sun N; Xue L; Yang Z; Fang L; Zhang Z; Luo Y; Gao S; Xue Q; Mu J; Gao Y; Tan F; He J
    J Cancer Res Clin Oncol; 2022 Apr; 148(4):943-954. PubMed ID: 34013382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Failure of neoadjuvant chemotherapy for resectable esophageal squamous cell carcinoma.
    Okamura A; Watanabe M; Mine S; Kurogochi T; Yamashita K; Hayami M; Imamura Y; Ogura M; Ichimura T; Takahari D; Chin K
    Dis Esophagus; 2017 Sep; 30(9):1-8. PubMed ID: 28859367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant Chemoradiotherapy with Cisplatin Plus Fluorouracil for Borderline Resectable Esophageal Squamous Cell Carcinoma.
    Suzuki T; Okamura A; Watanabe M; Mine S; Imamura Y; Asari T; Osumi H; Nakayama I; Ichimura T; Ogura M; Ooki A; Takahari D; Yamaguchi K; Chin K
    Ann Surg Oncol; 2020 May; 27(5):1510-1517. PubMed ID: 31820213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distribution of Lymph Node Metastasis in Esophageal Squamous Cell Carcinoma After Trimodal Therapy.
    Hamai Y; Emi M; Ibuki Y; Kurokawa T; Yoshikawa T; Ohsawa M; Hirohata R; Murakami Y; Nishibuchi I; Imano N; Nagata Y; Okada M
    Ann Surg Oncol; 2021 Mar; 28(3):1798-1807. PubMed ID: 32885399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Programmed death-1 ligands and tumor infiltrating T lymphocytes in primary and lymph node metastasis of esophageal cancer patients.
    Konno-Kumagai T; Fujishima F; Nakamura Y; Nakano T; Nagai T; Kamei T; Sasano H
    Dis Esophagus; 2019 Mar; 32(3):. PubMed ID: 30085020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Associated factors of postoperative relapse and metastasis in pT1bN0M0-pT4aN0M0 thoracic esophageal squamous cell carcinoma].
    Pan W; Xiang Y; Gu Z; Ji C; Mao T; Fang W
    Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Sep; 20(9):1045-1049. PubMed ID: 28900998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.